ERBB2 and neoplasm: Eighteen patients had biopsied tumor tissue and matched plasma at BL (Table S3), among which a significant concordance of 94.4% (17/18) was achieved (Table S4), verifying that plasma ERBB2 could be used as an alternative method for the screening of HER2‐targeted population.